Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Esophageal Neoplasm
Interventions
OTHER

Restrictive group

"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."

OTHER

Liberal group

"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."

Trial Locations (1)

10 000

"Department of Thoracic surgery Jordanovac University Hospital Centre Zagreb", Zagreb

All Listed Sponsors
lead

Klinički Bolnički Centar Zagreb

OTHER

NCT02033213 - Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial | Biotech Hunter | Biotech Hunter